HC Wainwright reiterated their buy rating on shares of Arbutus Biopharma (NASDAQ:ABUS – Free Report) in a report published on Friday, Benzinga reports. They currently have a $6.00 target price on the biopharmaceutical company’s stock. Separately, StockNews.com lowered shares of Arbutus Biopharma from a buy rating to a hold rating in a research note on […]
Arbutus Biopharma's (ABUS) "Buy" Rating Reiterated at HC Wainwright theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Arbutus Biopharma's (ABUS) Buy Rating Reiterated at Chardan Capital themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Operator: Good day, and thank you for standing by. Welcome to the Arbutus Biopharma Q2 Conference Call. [Operator Instructions] Please be advised that today s conference is being recorded.
Arbutus Biopharma Corporation: Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.